Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Samsung Biologics

  • Biosimilars: 10 Drugs to Watch
    ... On April 5, Lonza issues statement denying news reports that it will end its biosimilar joint venture with Teva 4 Samsung Biologics: Venture between Samsung and Quintiles halts ...
    4-22-2013
  • Electronics Giants Set Sights on Biotech
    A month earlier, Samsung Bioepis-a Samsung-Biogen Idec biologics joint venture-said it would collaborate with Merck & Co. to create "multiple pre-specified" undisclosed ...
    4-1-2013
  • Biosimilars: Not So Far So Fast
    ... into the biologics and vaccines division of Merck Research Laboratories. Merck announced this February that it had entered into an agreement with Samsung Bioepis to develop ...
    3-15-2013
  • Electronics Giant Samsung Makes First Big Biotech Play
    Samsung Bioepis, which is a joint venture formed last year by Samsung Biologics and Biogen Idec to focus on biosimilars, has a R&D center based in Song-do Incheon, Korea. ...
    2-20-2013
  • Biosimilars Now Just About Ready to Roll
    Sandoz initiated two Phase III trials for biosimilar versions of two Amgen biologics. ... Samsung and Biogen Idec announced in December 2011 that they have entered into an ...
    9-1-2012
  • Firms Are Upping the Stakes on mAb Biosimilar Development
    ... will be funded with $255 million from Samsung and $45 million from Biogen; Biogen will ... at launching six or more follow-on biologics between 2012 and 2017. The JV is ...
    12-16-2011
  • Biogen Idec, Samsung Establish $300M Biosimilar Joint Venture
    $225 million for an 85% stake. The venture will essentially contract with Biogen Idec and Samsung Biologics for technical development and manufacturing services, the firms state. ...
    12-6-2011
  • Samsung Stakes Out Biopharma Position
    Firm Seeks to Replicate Success in Electronics Industry in Biopharmaceutical Manufacturing Researchers at Samsung Biologics have extensive experience working with many types of ...
    11-15-2011
  • Fujifilm and Dr. Reddy's Ink Pact Covering Generic Drugs in Japan
    Fujifilm gains all the equity interest in both Diosynth and MSD Biologics, including ... first quarter of 2012. The other hi-tech company making a play in biopharma is Samsung. ...
    7-28-2011
  • Biosimilars Proceed with Caution from Starting Gate
    ... for demonstrating the equivalence of biologics," he says, not to mention surrogate ... Even Samsung, the consumer electronics giant, announced a $389 billion investment in ...
    5-15-2011
  • High-Tech Companies Buy Into Biomanufacturing
    In February Samsung reported plans to set up a KRW 300 billion (roughly $263.9 million) JV ... Fujifilm gains all the equity interest in both Diosynth and MSD Biologics, including ...
    3-18-2011

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll